The increasing popularity of processed convenience foods could be a factor.
Consuming too much phosphorus increases the risk of left ventricular hypertrophy in women, study finds
Combined with use of a binder, this approach raised serum albumin while maintaining target phosphorus levels.
Factors unrelated to mineral metabolism may contribute to the association between high FGF-23 and death in dialysis patients.
Researchers made the discovery in a study of individuals with normal kidney function.
Proteinuria also is linked to high cholesterol.
Reducing phosphate burden may decrease proteinuria and slow progression of renal disease in patients with chronic kidney disease.
Nearly 11% of hemodialysis (HD) patients who discontinued use of a phosphate binder did so because of side effects.
Oral sodium bicarbonate may ease hyperphosphatemia in peritoneal dialysis (PD) patients with metabolic acidosis.
Dietary phosphorus may have an effect on the progression of autosomal dominant polycystic kidney disease.
Serum phosphorus concentrations are significantly lower in elderly hemodialysis (HD) patients compared with younger patients.
Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.
Lanthanum carbonate acts in synergy with dietary phosphate restriction to decrease levels of fibroblast growth factor 23 (FGF-23) in patients with chronic kidney disease (CKD) and normal phosphate levels.
Hyperparathyroidism develops prior to significant hyperphosphatemia in patients with chronic kidney disease (CKD) but not on dialysis.
New findings presented at Kidney Week 2012 suggest that target serum phosphorus levels in patients on maintenance hemodialysis (MHD) may need to be defined.
High serum levels of (iPTH) and dietary protein intake are associated with an increased risk of hyperphosphatemia in patients on MH.
Greater body mass index and waist circumference increases risk of secondary hyperparathyroidism, hyperphosphatemia, and hypertension.
Linked to lower urinary, serum phosphorus, but promote progression of vascular calcification
An unexpected impact may be excessive phosphorus retention.
PARIS—Diuretics may raise phosphate levels and increase the likelihood of hyperphosphatemia in patients with chronic kidney disease.
PARIS—Raising the dose of the calcium-free phosphate binder lanthanum carbonate from a lower conventionally used dose of 2,250 or less to 3,000 mg/day may reduce phosphorus levels in patients with chronic kidney disease (CKD) and hyperphosphatemia.
NATIONAL HARBOR, Md.—An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
LAS VEGAS—A novel interactive Web-based phosphorus education tool may help to improve phosphorus control in dialysis patients, according to a report at the National Kidney Foundation's Spring Clinical Meetings.
LAS VEGAS—Albumunuria, proteinuria, lower estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy are significantly associated with hyperphosphatemia and anemia, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
LAS VEGAS—Fibroblast growth factor 23 (FGF-23) is not significantly associated with dietary phosphorus or urinary phosphorus excretion, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
LAS VEGAS—Lanthanum carbonate binds dietary phosphorus more effectively than sevelamer, researchers reported here at the National Kidney Foundation's Spring Clinical Meetings.
LAS VEGAS—New findings presented at the National Kidney Foundation's Spring Clinical Meetings confirm the phosphorus-lowering effects of extended-release niacin in fixed-dose combination with laropiprant (ERN-L) in dyslipidemic patients with stage 3 chronic kidney disease (CKD).
Crushing lanthanum carbonate and mixing it with food can be an option for hemodialysis (HD) patients with hyperphosphatemia who are unable to chew or swallow whole tablets, researchers reported in Hemodialysis International (2011;15:95-99).
An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease. Key to these efforts is the availability of clinically accessible biomarkers that can help distinguish between a wide variety of bone and mineral disturbances related to kidney failure.